Hyqvia

Human normal immunoglobulin, the active ingredient in Hyqvia, is an Immunoglobulin (IgG) replacement therapy presented as a solution for subcutaneous infusion for subcutaneous use. It supplies passive immunity to patients with primary immunodeficiency diseases who require regular immunoglobulin replacement to maintain protective antibody levels.

GNH USA supplies Hyqvia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution across multiple regions.

Hyqvia is used in the management of primary immunodeficiency disorders, delivering immunoglobulin replacement to restore antibody levels. - Primary Common Variable Immunodeficiency (CVID): reduces frequency and severity of infections by providing necessary IgG antibodies. - X‑linked Agammaglobulinemia (XLA): supplies missing immunoglobulins to support immune function. - Severe Combined Immunodeficiency (SCID) post‑hematopoietic stem cell transplant: aids immune reconstitution during recovery.

Hyqvia may be associated with a range of adverse reactions following subcutaneous administration.

Common Side Effects: - Infusion site erythema or swelling: mild redness or puffiness at the injection site. - Headache: transient pain in the head region. - Nausea: mild to moderate feeling of queasiness. - Fatigue: temporary tiredness or lack of energy.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: blood clots that may lead to vascular complications. - Renal dysfunction: impaired kidney function, especially with high cumulative doses. - Aseptic meningitis: inflammation of the meninges without infection.

Before initiating Hyqvia therapy, consider the following precautions to ensure safe and effective use. - Assess immunoglobulin levels: confirm deficiency and need for replacement therapy. - Monitor for infection risk: patients with active infections may require treatment postponement. - Evaluate renal function: baseline and periodic kidney tests are recommended. - Review vaccine schedule: live vaccines should be avoided during treatment. - Consider anticoagulant therapy: monitor bleeding risk if patient is on anticoagulants. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Hyqvia can interact with other medicines; awareness of major and moderate interactions helps manage patient safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause uncontrolled infection due to altered immune response. - High‑dose aspirin or NSAIDs: increase risk of bleeding when combined with hyaluronidase‑mediated tissue changes. - Monoclonal antibodies targeting IgG: may reduce efficacy of immunoglobulin therapy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as hyaluronidase may affect subcutaneous absorption. - Renally cleared antibiotics (e.g., aminoglycosides): watch for additive renal toxicity. - Inactivated vaccines: may have reduced immunogenicity; assess antibody response. - Other immunoglobulin products: stagger administration to avoid overlapping infusion sites.